The treatment response (following anti-PD-1/PD-L1 antibody coadministration) to that effect was also categorised into three groups of marked, mild, and no effect based on tumour weight of <300 mg, 300–600 mg, and 600 mg, respectively, and these were compared to an isotype control group [48]. The gene discussed is CD274; the disease is neoplasm.